HighTower Advisors
CPRX

HighTower Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

HighTower Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,500
Closed -$2K – 2569
2020
Q2 		$2K Buy
+2,500
New +$11.2K ﹤0.01% 2380
2019
Q4 		– Sell
-2,900
Closed -$2K – 2412
2019
Q3 		$2K Buy
+2,900
New +$15.4K ﹤0.01% 2361

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HighTower Advisors's CPRX Position: Q1 2026 in Review

HighTower Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 10% in Q1 2026, buying an estimated $59.3K and bringing the position to 26,333 shares worth $652K. The position accounts for ﹤0.01% of the portfolio, ranked #2498.

HighTower Advisors first reported a position in CPRX in Q4 2017 and has held it in 13 quarters since. The position peaked at $1.97M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • HighTower Advisors held 26,333 shares of Catalyst Pharmaceutical worth $652K as of Q1 2026.
  • HighTower Advisors bought 2,489 Catalyst Pharmaceutical shares in Q1 2026, an estimated $59.3K.
  • Catalyst Pharmaceutical made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2498 holding.
  • HighTower Advisors first reported a position in Catalyst Pharmaceutical in Q4 2017 and has held it in 13 quarters since.
  • HighTower Advisors's Catalyst Pharmaceutical position peaked at $1.97M in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.